Medknow Publications on behalf of the Neurological Society of India
Vol. 54, No. 4, 2006, pp. 354-358
Bioline Code: ni06128
Full paper language: English
Document type: Research Article
Document available free of charge
Neurology India, Vol. 54, No. 4, 2006, pp. 354-358
© Copyright 2006 Neurology India.
Refractory status epilepticus|
Refractory status epilepticus (RSE) is a common problem in intensive care units and emergency departments. The important risk factor predisposing patients with SE to RSE is delay in receiving treatment. Self-sustaining SE is associated with progressive, time-dependent development of pharmacoresistance. Early termination of convulsive SE by aggressive treatment is the best way to prevent RSE. RSE once develop, requires more aggressive treatment as it is associated with higher mortality and morbidity. To date, no randomized controlled trials have been done for RSE. The most experience exists with coma inducing agents like pentobarbital, midazolam and propofol. New evidence suggests for the possible role of newer AEDs.
Anesthetic agents, burst suppression, midazolam, pentobarbital, propofol, refractory status epilepticus.
Alternative site location: http://www.neurologyindia.com